September 13, 2018 05:57 AM EDT

BIO, Allergan and Roche call for FDA flexibility with patient experience data

Zachary Brennan

Senior Editor

Industry group BIO and biopharma companies Allergan and Roche are calling for the FDA to be flexible in its approach for using patient experience data …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BIO, Allergan and Roche call for FDA flexibility with patient experience data

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Sanofi's BTK inhibitor again slows MS progression, but liver enzymes continue to be tricky

Novo says its CB1 drug helped shed weight, but efficacy and safety questions remain

Lexicon's president to step down as decision date looms; Sarepta welcomes Lilly, GSK vet to board

Biotech VC firm outlines plans for $100M fund

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Breaking down silos with a new quantitative approach to drug development

BIO, Al­ler­gan and Roche call for FDA flex­i­bil­i­ty with pa­tient ex­pe­ri­ence da­ta

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

BIO, Allergan and Roche call for FDA flexibility with patient experience data